PT1417222E - Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante - Google Patents

Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante Download PDF

Info

Publication number
PT1417222E
PT1417222E PT02751526T PT02751526T PT1417222E PT 1417222 E PT1417222 E PT 1417222E PT 02751526 T PT02751526 T PT 02751526T PT 02751526 T PT02751526 T PT 02751526T PT 1417222 E PT1417222 E PT 1417222E
Authority
PT
Portugal
Prior art keywords
neutralizing
arg
amino acid
acid residue
residue selected
Prior art date
Application number
PT02751526T
Other languages
English (en)
Inventor
Arnaldo Caruso
Jose Sebastian Franzone
Original Assignee
Medestea Int Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001TO000795A external-priority patent/ITTO20010795A1/it
Priority claimed from ITTO20011042 external-priority patent/ITTO20011042A1/it
Application filed by Medestea Int Spa filed Critical Medestea Int Spa
Publication of PT1417222E publication Critical patent/PT1417222E/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT02751526T 2001-08-07 2002-08-05 Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante PT1417222E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001TO000795A ITTO20010795A1 (it) 2001-08-07 2001-08-07 Polipeptide isolato basato sulla sequenza della proteina p17 utile come vaccino anti-hiv.
ITTO20011042 ITTO20011042A1 (it) 2001-11-02 2001-11-02 Polipeptidi isolati basati sulla sequenza della proteina p17 di hiv utili come vaccino anti-hiv.

Publications (1)

Publication Number Publication Date
PT1417222E true PT1417222E (pt) 2010-10-12

Family

ID=26332884

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02751526T PT1417222E (pt) 2001-08-07 2002-08-05 Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante

Country Status (8)

Country Link
US (1) US7541036B2 (pt)
EP (1) EP1417222B1 (pt)
AT (1) ATE478089T1 (pt)
DE (1) DE60237373D1 (pt)
DK (1) DK1417222T3 (pt)
PT (1) PT1417222E (pt)
RU (1) RU2337922C9 (pt)
WO (1) WO2003016337A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20020286A1 (it) * 2002-03-29 2003-09-29 Medestea Int Spa Uso della proteina p17 isolata per la preparazione di un medicamento atto ad inibire gli effetti immunostimolanti che la proteina prodotta d
MXPA05011997A (es) * 2005-11-08 2007-05-07 Univ Mexico Nacional Autonoma Vacuna intranasal contra la enfermedad ocasionada por escherichia coli enterotoxigenica.
WO2008157483A2 (en) * 2007-06-14 2008-12-24 The Research Foundation Of State University Of New York Polypeptides and methods of use
ITTO20080027A1 (it) * 2008-01-15 2009-07-16 Medestea Res & Production S P A Forma troncata della proteina p17 di hiv.
IT1401359B1 (it) * 2010-03-31 2013-07-18 Medestea Res & Production S P A Anticorpo monoclonale diretto contro la proteina p17 di hiv, atto a neutralizzare il legame fra la proteina p17 e il recettore della proteina p17 (p17r)
RU2475264C2 (ru) * 2010-12-29 2013-02-20 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства Вакцина против вич/спид
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
CA3100693A1 (en) 2018-05-17 2019-11-21 Stuart Lindsay Device, system and method for direct electrical measurement of enzyme activity
CA3128358A1 (en) * 2019-01-30 2020-08-06 Arizona Board Of Regents On Behalf Of Arizona State University Bioelectronic circuits, systems and methods for preparing and using them
RU2727673C1 (ru) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Антитела против белка р17 ВИЧ-1 субтипа А
US11913070B2 (en) 2020-02-28 2024-02-27 Arizona Board Of Regents On Behalf Of Arizona State University Methods for sequencing biopolymers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use

Also Published As

Publication number Publication date
ATE478089T1 (de) 2010-09-15
WO2003016337A1 (en) 2003-02-27
RU2337922C9 (ru) 2009-02-10
DE60237373D1 (de) 2010-09-30
RU2337922C2 (ru) 2008-11-10
US20040249124A1 (en) 2004-12-09
RU2004106618A (ru) 2005-07-10
DK1417222T3 (da) 2010-12-13
EP1417222A1 (en) 2004-05-12
EP1417222B1 (en) 2010-08-18
US7541036B2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
AU640619B2 (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
AU7075496A (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
EP1420821B8 (en) Immunologically significant herpes simplex virus antigens and methods for using same
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
ATE199394T1 (de) Gag-env fusion-antigen aus hiv
RU2002126396A (ru) Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
Spetzler et al. A novel strategy for the synthesis of the cysteine‐rich protective antigen of the malaria merozoite surface protein (MSP‐1) Knowledge‐based strategy for disulfide formation
WO2003022879B1 (en) Peptides mimicking a cryptic epitope of gp41 hiv-1 and antibodies directed against them
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2006078268A3 (en) A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2000058438A3 (en) Conformationally constrained peptides
Devadas et al. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection
Huang et al. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade
WO2005062871A3 (en) Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
DE60325227D1 (pt)
ES2350901T3 (es) Polipéptidos aislados basados en el epítopo neutralizante de la proteína p17 del vih útiles como vacunas, y anticuerpos anti-p17 neutralizantes que reconocen específicamente dicho epítopo neutralizante.
WO2003099995A3 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene